Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
GALT
GALT
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
GALT News
Pulsenmore Soars 280% on Ouma Health Collaboration
Jun 25 2026
NASDAQ.COM
Boundless Bio Merges with Serapha in All-Stock Deal
Jun 24 2026
NASDAQ.COM
Galectin Therapeutics Reaches Agreement with FDA for Late-Stage Trial
Jun 23 2026
stocktwits
Galectin Aligns with FDA on Belapectin Regulatory Path for MASH Cirrhosis
Jun 23 2026
NASDAQ.COM
Galectin Reaches Agreement with FDA on Phase 3 Trial for Belapectin
Jun 23 2026
seekingalpha
Galectin Reaches Key Agreement with FDA on Belapectin Approval Path
Jun 23 2026
Newsfilter
Galectin Therapeutics Q1 Earnings Report Analysis
May 15 2026
seekingalpha
Galectin Therapeutics Reports Positive Phase 2b Results for Belapectin in MASH Cirrhosis
May 11 2026
NASDAQ.COM
Galectin Therapeutics Reports FY EPS Beat Expectations
Mar 31 2026
seekingalpha
Galectin Therapeutics Under Investigation, Stock Plummets 28.9%
Jan 22 2026
PRnewswire
Galectin Therapeutics Under Investigation, Stock Plummets 28.9%
Jan 15 2026
PRnewswire
Galectin Therapeutics Faces 28.9% Stock Drop Following FDA Response on Belapectin Trial
Jan 08 2026
PRnewswire
Galectin Therapeutics Faces Securities Fraud Investigation as Stock Plummets 28.9%
Jan 06 2026
Globenewswire
Galectin Therapeutics Faces 28.9% Stock Drop Following FDA Response on Belapectin Trial
Dec 30 2025
Globenewswire
Galectin Therapeutics Shares Plunge 28.9% Following FDA Response on Belapectin Development
Dec 30 2025
Businesswire
Galectin Secures $10M Credit Line, FDA Provides Guidance on Regulatory Pathway
Dec 26 2025
NASDAQ.COM
Show More News
